Publications by authors named "Pablo Altman"

Claim this Profile
D
Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence Study.
Jamuna K Krishnan, Gerard J Criner, Bilal H Lashari, Fernando J Martinez, Victor Kim, Pablo Altman

Chronic Obstr Pulm Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database.
Jamuna K Krishnan, Fernando J Martinez, Pablo Altman, Ver Luanni F Bilano, Edward Khokhlovich

Chronic Obstr Pulm Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential systemic effects of acquired CFTR dysfunction in COPD.
Marc Miravitlles, Gerard J Criner, Marcus A Mall, Steven M Rowe, Claus F Vogelmeier, Pablo Altman

Respir Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.
Marcus A Mall, Gerard J Criner, Marc Miravitlles, Steven M Rowe, Claus F Vogelmeier, Pablo Altman

Eur Respir J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an inhaled anti-TSLP therapy for asthma.
Paul M O'Byrne, Reynold A Panettieri, Christian Taube, Caterina Brindicci, Margaret Fleming, Pablo Altman

Pulm Pharmacol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rationale for development of ligelizumab in food allergy.
Robert A Wood, R Sharon Chinthrajah, Alexander Eggel, Ivan Bottoli, Aurelie Gautier, Pablo Altman

World Allergy Organ J· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncontrolled asthma across GINA treatment steps 2 - 5 in a large US patient cohort.
William W Busse, Juanzhi Fang, Jessica Marvel, Hengfeng Tian, Pablo Altman

J Asthma· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).
Philippe Gevaert, Claus Bachert, Jorge Fernando Maspero, Mandy Cuevas, David Steele, Pablo Altman

J Allergy Clin Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacology of the prostaglandin D receptor 2 (DP) receptor antagonist, fevipiprant.
Chris Brightling, Swarupa Kulkarni, Bart N Lambrecht, David Sandham, Markus Weiss, Pablo Altman

Pulm Pharmacol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of the prostaglandin D receptor 2 and its downstream effects on the pathophysiology of asthma.
Christopher E Brightling, Guy Brusselle, Pablo Altman

Allergy· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety.
David Price, Mario Castro, Arnaud Bourdin, Sebastian Fucile, Pablo Altman

Eur Respir Rev· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient perception of Breezhaler and Ellipta device feedback mechanisms in COPD: The ADVANTAGE Study.
Pablo Altman, Miguel A Bergna, Gabriel R Garcia, Tadhg Guerin, Andrea V Pino

Curr Med Res Opin· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis.
Georgios Ntritsos, Jacob Franek, Lazaros Belbasis, Maria A Christou, Georgios Markozannes, Pablo Altman

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation.
Christian Domingo, Oscar Palomares, David A Sandham, Veit J Erpenbeck, Pablo Altman

Respir Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
Pablo Altman, Luis Wehbe, Juergen Dederichs, Tadhg Guerin, Brian Ament

BMC Pulm Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
Anthony D'Urzo, Giovanni Bader, Steven Shen, Pankaj Goyal, Pablo Altman

NPJ Prim Care Respir Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.
James F Donohue, Keith A Betts, Ella Xiaoyan Du, Pablo Altman, Pankaj Goyal

Int J Chron Obstruct Pulmon Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Gustavo J Rodrigo, David Price, Antonio Anzueto, Dave Singh, Pablo Altman

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist.
Thys van der Molen, Job F M van Boven, Terence Maguire, Pankaj Goyal, Pablo Altman

Br J Clin Pharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
Anthony D D'Urzo, Edward M Kerwin, Kenneth R Chapman, Marc Decramer, Robert DiGiovanni, Pablo Altman

Int J Chron Obstruct Pulmon Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.
Donald A Mahler, Huib A M Kerstjens, James F Donohue, Roland Buhl, David Lawrence, Pablo Altman

Respir Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
Andrea Rossi, Thys van der Molen, Ricardo del Olmo, Alberto Papi, Luis Wehbe, Pablo Altman

Eur Respir J· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.
Amir Sharafkhaneh, Aylin E Altan, Gene L Colice, Nicola A Hanania, James F Donohue, Pablo R Altman

Respir Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing unmet needs in the treatment of COPD.
Francesco Patalano, Donald Banerji, Peter D'Andrea, Robert Fogel, Pablo Altman

Eur Respir Rev· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.
Christopher M Blanchette, Nicholas J Gross, Pablo Altman

Am Health Drug Benefits· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis